Shire Says Investors More Favorable Now To Baxalta Bid
This article was originally published in The Pink Sheet Daily
Executive Summary
Falling valuation of biotech companies is a greater hindrance to merging with Baxalta than perceived lack of enthusiasm by shareholders, CEO tells earnings call.